28 October 2025
28 October 2025
The Q3 update comes amid a deal-making spree for the big-pharma to stave off generic headwinds.
Despite already having its own ADC in development for prostate cancer, GSK is doubling down on the modality.
An investigation by the board’s audit committee found evidence of malpractice, meaning certain company sales statements were “inaccurate or incomplete”.
In the trial involving 172 patients, Winrevair showed a 76% reduction in major mortality or morbidity risk.
Following the completion of a Phase II trial of sutacimig, Hemab is preparing to progress to a registration trial in 2026.
By combining their expertise, the companies expect to establish a model that will advance precision oncology.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
